JPMorgan reports 4.4% stake in REGENXBIO

JPMorgan Chase & affiliates reported beneficial ownership of 2,279,362 shares of REGENXBIO Inc. The filing, an amendment to a Schedule 13G/A, shows those shares represent 4.4% of the outstanding common stock (CUSIP 75901B107).

Rhea-AI Filing Summary

JPMorgan Chase & affiliates reported beneficial ownership of 2,279,362 shares of REGENXBIO Inc. The filing, an amendment to a Schedule 13G/A, shows those shares represent 4.4% of the outstanding common stock (CUSIP 75901B107). The report attributes 2,104,445 shares of sole voting power and 2,279,362 shares of sole dispositive power. Multiple JPMorgan entities are named as holders. The filing is signed by a JPMorgan vice president.

Key Figures

Beneficial ownership: 2,279,362 shares Percent of class: 4.4% Sole voting power: 2,104,445 shares +2 more

5 metrics

Beneficial ownership 2,279,362 shares reported on Schedule 13G/A

Percent of class 4.4% of REGENXBIO common stock

Sole voting power 2,104,445 shares sole power to vote or direct the vote

Sole dispositive power 2,279,362 shares sole power to dispose or direct disposition

CUSIP 75901B107 REGENXBIO common stock identifier

Key Terms

Schedule 13G/A, beneficially owned, sole dispositive power, parent holding company

4 terms

Schedule 13G/A regulatory

"Amendment No. 7 ) REGENXBIO Inc."

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficially owned regulatory

"Amount beneficially owned: 2,279,362"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole dispositive power regulatory

"Sole power to dispose or to direct the disposition of: 2,279,362"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

parent holding company regulatory

"Identification and Classification of the Subsidiary Which Acquired the Security"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does JPMorgan hold in REGENXBIO (RGNX)?

JPMorgan reports beneficial ownership of 2,279,362 shares, representing 4.4% of REGENXBIO common stock. The filing lists voting and dispositive powers and identifies multiple JPMorgan entities associated with the position.

Which JPMorgan entities are named in the Schedule 13G/A for RGNX?

The amendment names J.P. Morgan Securities LLC, JPMorgan Chase Bank, National Association, and J.P. Morgan Investment Management Inc. as entities connected with the reported beneficial ownership position.

What voting and dispositive powers does JPMorgan report on RGNX shares?

The filing reports 2,104,445 shares as sole voting power and 2,279,362 shares as sole dispositive power. Shared voting and dispositive powers are reported as 0 in the provided excerpt.

What document and dates are shown for JPMorgan's RGNX filing?

The excerpt is an Amendment No. 7 to a Schedule 13G/A referencing 05/29/2026 on the cover and signed on 06/04/2026 by a JPMorgan vice president, per the provided content.

Does the Schedule 13G/A indicate JPMorgan controls more than 5% of RGNX?

No. The filing states beneficial ownership is 4.4%, which is below the 5% threshold noted in the report. The form explicitly classifies the position as "Ownership of 5 percent or less of a class."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/04/2026 - 01:09 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 7)

REGENXBIO Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

75901B107

(CUSIP Number)

05/29/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 75901B107

1

Names of Reporting Persons

JPMORGAN CHASE & CO

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,104,445.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,279,362.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,279,362.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.4 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: REGENXBIO Inc.
(b)	Address of issuer's principal executive offices: 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MARYLAND, 20850.
Item 2.
(a)	Name of person filing: JPMORGAN CHASE & CO
(b)	Address or principal business office or, if none, residence: 270 Park Avenue,,New York, NY 10017
(c)	Citizenship: DE
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 75901B107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 2,279,362
(b)	Percent of class: 4.4 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 2,104,445
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 2,279,362
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. J.P. Morgan Securities LLC; JPMorgan Chase Bank, National Association; J.P. Morgan Investment Management Inc.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

JPMORGAN CHASE & CO

Signature:	Rachel Tsvaygoft
Name/Title:	Vice President
Date:	06/04/2026